Author

Srdan M. Dragovic

Observed names: Srdjan Dragovic, Srdjan M Dragovic, Srdjan M. Dragovic

Institution: Oncoinvent (Norway)

Observed institutions: Howard Hughes Medical Institute, Vanderbilt University, Yale University, Oncoinvent (Norway), Vanderbilt University Medical Center

ORCID: 0009-0008-2269-4476

Observed ORCID: 0009-0008-2269-4476

OpenAlex ID: A5118128353

Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling Pathways

2010 · Keunwook Lee, Prathyusha Gudapati, et al. · Immunity · 477

In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules

2006 · Jingbo Yan, Vrajesh V. Parekh, et al. · The Journal of Experimental Medicine · 172

Mosquito Saliva Serine Protease Enhances Dissemination of Dengue Virus into the Mammalian Host

2013 · Michael J. Conway, Alan M. Watson, et al. · Journal of Virology · 160

Immunization with AgTRIO, a Protein in Anopheles Saliva, Contributes to Protection against Plasmodium Infection in Mice

2018 · Srdjan M. Dragovic, Tolulope A. Agunbiade, et al. · Cell Host & Microbe · 51

Minor histocompatibility antigens: presentation principles, recognition logic and the potential for a healing hand

2010 · Charles T Spencer, Pavlo Gilchuk, et al. · Current Opinion in Organ Transplantation · 20

Proteasomes, TAP, and Endoplasmic Reticulum-Associated Aminopeptidase Associated with Antigen Processing Control CD4+ Th Cell Responses by Regulating Indirect Presentation of MHC Class II-Restricted Cytoplasmic Antigens

2011 · Srdjan M Dragovic, Timothy Hill, et al. · The Journal of Immunology · 14

Sculpting MHC class II–restricted self and non‐self peptidome by the class I Ag‐processing machinery and its impact on Th‐cell responses

2013 · Charles T. Spencer, Srdjan M. Dragovic, et al. · European Journal of Immunology · 9

Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al. · Molecular Cancer Therapeutics · 6

Table S2 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Figure S2 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Data from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Figure S3 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Figure S1 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Table S3 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Table S4 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Table S1 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Works count: 16

Citation count: 909

H-index: 7

I10-index: 6